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Abstract
BACKGROUND—By stimulating lipofibroblast maturation, parenterally administered PPARγ 
agonists promote lung homeostasis and injury repair in the neonatal lung. In this study, we 
determined whether PPARγ agonists could be delivered effectively via nebulization to neonates, 
and whether this approach would also protect against hyperoxia-induced lung injury.
METHODS—One-day old Sprague-Dawley rat pups were administered PPARγ agonists 
rosiglitazone (RGZ, 3 mg/kg), pioglitazone (PGZ, 3 mg/kg), or the diluent, via nebulization every 
24h; animals were exposed to 21% or 95% O2 for up to 72h. Twenty-four and 72h following 
initial nebulization, the pups were sacrificed for lung tissue and blood collection to determine 
markers of lung maturation, injury repair, and RGZ and PGZ plasma levels.
RESULTS—Nebulized RGZ and PGZ enhanced lung maturation in both males and females, as 
evidenced by the increased expression of markers of alveolar epithelial and mesenchymal 
maturation. This approach also protected against hyperoxia-induced lung injury, since hyperoxia-
induced changes in bronchoalveolar lavage cell and protein contents and lung injury markers were 
all blocked by nebulized PGZ.
CONCLUSIONS—Nebulized PPARγ agonist administration promotes lung maturation and 
prevents neonatal hyperoxia-induced lung injury in both males and females.
Introduction
Despite several technological and therapeutic advances over the last two or three decades, 
Bronchopulmonary Dysplasia (BPD) remains a significant cause of morbidity in very low 
birth weight infants. BPD is characterized by aberrations in premature lung development 
following exposure to conditions such as hyperoxia, volutrauma, inflammation, and/or 
atelectotrauma, resulting in significantly increased prematurity-related morbidity and 
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mortality. Therefore, attempts to advance lung maturity and develop lung-protective 
strategies have been the focus of research for many decades.
By stimulating alveolar interstitial lipofibroblast maturation, the nuclear transcription factor 
Peroxisome Proliferator-Activated Receptor gamma (PPARγ) has been demonstrated to play 
a key role in physiologic lung development and homeostasis (1–3). Lipofibroblasts have 
been demonstrated to play a central role in normal lung development by inducing alveolar 
epithelial-mesenchymal paracrine signaling, stimulating surfactant phospholipid and protein 
synthesis and by acting as endogenous antioxidants (1–2, 4). This is important since 
antenatal steroid administration, the contemporary standard intervention for enhancing fetal 
lung maturation, has significant limitations. For example, this therapy is effective in only 
50–70% of infants, is sex-specific, has a delayed onset of action, and with repeated use, it 
may result in significant somatic growth restriction and neurodevelopmental handicaps (5–
8). In view of the limited options for agents that can be used to stimulate lung maturation, 
alternate strategies for accelerating fetal lung maturation that are effective and safe are 
needed.
We have previously shown that the systemic administration of the PPARγ agonist 
rosiglitazone (RGZ), either antenatally or postnatally, enhances lung maturation and can 
prevent hyperoxia-induced acute neonatal lung injury without significantly affecting blood 
biochemical and metabolic profiles, both in the short- and long-terms, suggesting the 
therapeutic usefulness of PPARγ agonists in preventing and/or treating BPD (3, 9–13). 
However, in adults, systemically administered PPARγ agonists are known to be associated 
with significant side effects (14–16). Here, we determined whether PPARγ agonists could be 
delivered effectively via nebulization, and whether this would afford protection against 
hyperoxia-induced neonatal lung injury. Though we have previously used RGZ to study the 
effects of the PPARγ agonist class of agents on lung maturation, in this study, we also 
included pioglitazone (PGZ) because of its superior safety profile in adults when compared 
to RGZ (17, 18). Hypothesizing that PPARγ agonists given via nebulization would enhance 
lung maturation and block hyperoxia-induced lung injury, using a rat model, in this study, 
we determined whether the nebulized PPARγ agonists RGZ or PGZ stimulate lung 
maturation, protect against hyperoxia-induced acute neonatal lung injury, and affect extra-
pulmonary PPARγ-expressing organs. Lung maturation was assessed by determining the 
expression of key alveolar epithelial and mesenchymal molecular markers that are the 
hallmarks for the functional maturation of the developing lung, including expression of 
surfactant protein (SPs) B and C, choline incorporation into saturated phosphatidylcholine, 
and triolein uptake by the lung. To assess lung injury, in addition to these markers of lung 
maturation, lung morphometry, lung apoptosis, important intermediates of TGF-β activation 
and lung vascular markers (vascular endothelial-derived growth factor (VEGF) and platelet 
endothelial cell adhesion molecule (PECAM)-1), lung cytokines (IL-6, IL-1β, chemokine 
ligand 2 (CCL2), and macrophage migration inhibitory factor (MIF)), and bronchoalveolar 
lavage (BAL) fluid protein and cellular contents were analyzed.
As proof-of-principle for possible systemic effects of nebulized PPARγ, plasma levels of 
RGZ and PGZ, and PPARγ receptor expression in liver, heart, and kidney were determined 
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(PPARγ is expressed in a wide range of tissues such as, but not limited to, adipose tissue, 
heart, brain, skeletal muscle, liver, intestine, kidney, pancreas, and spleen).
Methods
Animal protocol
Pathogen-free, time-mated Sprague-Dawley rat dams were obtained from Charles River 
Laboratories (Hollister, CA) at day 16 of gestation, acclimatized in humidity- and 
temperature-controlled rooms with 12-hour light and dark cycles, and provided food and 
water ad libitum. On day 22 of pregnancy the dams delivered spontaneously. One-day-old 
rat pups breastfed ad libitum were used and were grouped into nebulizing groups (using a 
Lincare Nebulizer, PariRespiratory Equipment, Inc. Midlothian, VA) as follows: One set of 
pups was maintained in room air and exposed to either nebulized 1mL normal saline 
containing the diluent DMSO (Sigma Aldrich St Louis, MO) (60μL) and another set 
exposed to nebulized RGZ (Cayman Chemicals Ann Arbor, MI) or PGZ (Cayman 
Chemicals Ann Arbor, MI) (3mg/kg in 60 μL DMSO, diluted in 1 mL saline), nebulized 
over 30 minutes, in an enclosed chamber (28 × 17 × 12cm). Twenty-four hour later pups 
were sacrificed for tissue and blood collection. For assessing the protection against 
hyperoxia-induced neonatal lung injury by using nebulized PPARγ agonist administration, 
some control animals were maintained in room air and nebulized with 1 mL normal saline 
(containing the diluent DMSO), while the hyperoxia (95% O2) exposure group animals were 
treated with either 1 mL nebulized saline (containing the diluent DMSO) or nebulized PGZ 
(3mg/kg in 60 µL DMSO, diluted in 1mL saline), respectively, every 24h for up to 72h. 
Continuous 95% O2 exposure was achieved in a plexiglass chamber (77 × 64 × 37 cm) using 
a flow-through system. For monitoring of oxygen levels inside the chamber, a Ceramatec 
(MAXO2) oxygen analyzer (Maxtec Salt Lake City, Utah) was used. In yet another subset of 
animals, efficacy for protection against hyperoxia-induced lung injury using nebulized PGZ 
(1 mg/kg body weight) administration was compared with the parenteral (intraperitoneal) 
PGZ (3 mg/kg body weight) administration. After the experimental period, the pups were 
sacrificed using 0.1 mL euthasol (Sodium pentobarbital 390 mg + sodium phenytoin 50 
mg/ml; Virbac, Fort Worth, TX) per pup. To determine the effects of RGZ or PGZ on 
extrapulmonary PPARγ- expressing organs, heart, liver and kidney tissue was flash-frozen 
upon retrieval from the sacrificed animals. Blood was collected by cardiac puncture from 
each pup and frozen at −80°C for subsequent determination of plasma RGZ and PGZ levels. 
The lungs were collected and processed either immediately for [3H] choline incorporation 
and [3H] triolein uptake studies, or flash-frozen for later Western hybridization for the 
markers of lung maturation. All animal procedures were performed following the guidelines 
of the National Institute of Health for the care and use of laboratory animals, and approved 
by the Los Angeles Biomedical Research Institute, Animal Care and Use Committee.
Bronchoalveolar lavage collection
Pups were euthanized using pentobarbital (100 mg/kg i.p.), and a 27-gauge angiocatheter 
was ligated in place for BAL collection. Two 0.5-ml BALs were slowly performed by 
instilling 0.5 mL PBS + 5 mM EDTA. Retrieved solutions were pooled and centrifuged at 
Morales et al. Page 3
Pediatr Res. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
400 × g for 10 min. Sediments were analyzed for total cell counts and supernatants were 
snap-frozen in liquid nitrogen and subsequent analysis.
Protein extraction and Western blot analysis
Liquid nitrogen flash-frozen lung tissue was homogenized with a tissue grinder in lysis 
buffer (RIPA buffer) containing 1 mM EDTA and EGTA each (Boston Bioproducts 
Ashland, MA), supplemented with 1 mM PMSF, phosphate inhibitor (Sigma-Aldrich, St. 
Louis, MO), and complete proteinase inhibitor cocktail (Roche Diagnostics, Indianapolis, 
IN). For each sample, fifty micrograms of total protein were denatured with SDS-PAGE 
sample buffer and electrophoresed in a 10% SDS polyacrylamide gel. Resolved samples 
were then transferred onto a 0.45-μm nitrocellulose or PVDF membrane, which, after 
blocking with TBS-Tween (TBST) + 5% milk, were probed with primary antibodies 
[PPARγ (1:500), Adipocyte Differentiation-Related Protein, ADRP (1:200), Leptin (1:200), 
SPC (1:250), SPB (1:250), SMAD7 (1:150), ALK-5 (1:200), BcL-2 (1:350), Bax (1:600), 
Fibronectin (1:250), all from Santa Cruz Biotechnology, (Santa Cruz, CA); P-SMAD3 
(1:200) from Cell Signaling Technology, Inc., Danvers, MA); GAPDH (1:10,000; MAb 374 
(Chemicon, Temecula, CA)] overnight at 4°C, followed by appropriate secondary antibody 
and Super-Signal Chemiluminescent substrate (Pierce Chemicals, Rockford, IL). 
Photographic film (Denville Scientific, Metuchen, NJ) was used to quantitate protein bands, 
which were measured by densitometry using a scanning densitometer (Eagle Eye, 
Stratagene, La Jolla, CA) and expressed relative to accompanying GAPDH bands as relative 
units.
Measurement of rate of surfactant phospholipid synthesis
De novo surfactant phospholipid synthesis, triglyceride uptake and incorporation of 
[methyl-3H]-choline chloride (NEN Dupont, Boston) into saturated phosphatidylcholine in 
cultured lung explants were determined as described previously (13).
Lung morphometry
Lung morphometry was performed as described previously (3, 10).
Immunofluorescence staining
For immunofluorescence staining, rat lungs were inflated in situ with 4% paraformaldehyde 
in phosphate buffer at a standard inflation pressure of 5 cm H2O for 4h at 4°C. The lungs 
were subsequently transferred to PBS containing 30% sucrose (wt/vol) until equilibrated in 
the cold (4°C). After fixation, 5-μm paraffin sections were treated three times with Histo-
Clear (National Diagnostics, Atlanta, GA) for 5 min, and then rehydrated by a sequential 
ethanol wash. Sections were then washed twice for 10 min with PBS, and blocked for 1h in 
PBS-5% normal goat serum-0.2% Triton X-100. Sections were incubated with primary 
antibodies for 1h at room temperature, and then with the appropriate secondary antibody for 
1 h, also at room temperature. Antibodies used included PECAM (primary antibody, 1:10, 
BD Biosciences, San Jose, CA); secondary antibody, 1:100, Alexa Fluor, anti-rabbit 568 
red); BCL-2 (primary antibody, 1:100 Santa Cruz, Santa Cruz, CA; secondary antibody, 
1:100, Alexa Fluor, anti-rabbit 488 green); Bax (primary antibody, 1:100, Santa Cruz; 
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secondary antibody, 1:100, Alexa Fluor, anti-rabbit 568 red). The sections were washed with 
phosphate buffered saline and then mounted with ProLong Gold antifade reagent with DAPI 
(Invitrogen) for visualization under a fluorescence microscope.
Real Time RT-PCR
For lung cytokine assay, RNA extraction and q-RT-PCR was performed according to 
previously described methods (19). RT-PCR primers used included IL6: F5′-
CTTCCTACCCCAACTTCCAA-3′ and R5′-ACCACAGTGAGGAATGTCCA-3′ (191 bp); 
IL-1β: F5′-AGAGTGTGGATCCCAAACAA-3′ and R5′-
AGTCAACTATGTCCCGACCA-3′ (186 bp); CCL2: F5′-
TTGTCACCAAGCTCAAGAGA-3′ and R5′-GGTTGTGGAAAAGAGAGTGG-3′ (206 
bp); and MIF: F5′-AGAACCGCAACTACAGCAAG-3′ and R5′-
ACGGGTGGATAAACACAGAA-3′ (208 bp). The normalization control was 18S 
ribosomal RNA. Data were analyzed using a threshold level of fluorescence that was in the 
linear range of the PCR reaction. The CT value for 18S ribosomal RNA was subtracted from 
the CT value for the gene of interest to obtain a delta CT (∆CT) value. The relative fold-
change for each gene was calculated using the ∆∆CT method. Results were expressed as the 
mean ± SE, and considered statistically significant at P < 0.05.
Measurement of RGZ and PGZ in plasma and lungs
RGZ and PGZ were measured by a high-performance liquid chromatography (HPLC) 
gradient program using a 50:50 (or 1:1) mixture of acetonitrile and methanol (solvent A), 
and 50mM ammonium acetate buffer, pH 8.0 (solvent B). The HPLC column was a 
Whatman mBondapak C18 analytic column (3.6 × 150 mm). Elution of RGZ and PGZ was 
accomplished with a timed gradient program beginning with 100% solvent B, 5 min; then 
changed to 50% solvent B for 20min; followed by 95% solvent B for 5 min and held for 10 
min at this percentage of 95% solvent B. RGZ and PGZ had retention times of 29 ± 0.5 min, 
and 15 ± 0.5 min, respectively, and the amounts of RGZ and PGZ were calculated from a 
standard curve for pure RGZ run in tandem for each assay.
Measurement of plasma cardiac troponin I levels
Plasma cardiac troponin I levels were determined by a rat cardiac Tn-I ELISA kit as per the 
manufacturer's protocol (Life Diagnostics, West Chester, PA) (detection limit of 0.156 
ng/mL, and 100% specificity).
Statistical analysis
The experiments were done at least 3 independent times. The experimental data was 
analyzed using one-way ANOVA, with Tukey’s post-hoc analysis as appropriate. The 
results are expressed as means ± SD. P value of < 0.05 was considered to represent 
statistically significant differences between the groups.
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Results
Effect of nebulized RGZ and PGZ on alveolar differentiation markers
Twenty-four hours following nebulization, compared to the controls, RGZ and PGZ 
increased the expression of lung epithelial differentiation markers (SPB and SPC) in both 
females and males (Figure 1A), though there were no differences in response between the 
two genders. Since our laboratory has previously shown that mesenchymal PPARγ signaling 
is key to alveolar differentiation, we determined the effects of nebulized PGZ and RGZ on 
PPARγ and its down-stream targets ADRP and leptin. Twenty-four hours following 
nebulization, the expression of these markers was significantly increased in both females 
(PPARγ, ADRP and leptin, with both PGZ and RGZ), and males (PPARγ, ADRP and leptin 
with PGZ, and PPARγ and ADRP with RGZ) (Figure 1B). The effects of nebulized PGZ 
and RGZ on overall alveolar maturation are also reflected by functional alveolar markers 
such as a significantly increased rate of [3H] choline incorporation into saturated 
phosphatidylcholine (Figure 1C), and increased rates of triolein uptake (Figure 1D) in 
response to both PGZ and RGZ.
Gender-specific effects of RGZ and PGZ nebulization on markers of alveolar maturation
At the 24h time-point, there were no major differences in increases in epithelial (Figure 2A) 
and mesenchymal (Figure 2B) markers of alveolar maturation in males versus females 
following exposure to nebulized RGZ or PGZ. Similarly, there were no significant 
differences in male and female responses for the markers of overall alveolar maturation; 
hence, the combined gender data for [3H] choline incorporation into saturated 
phosphatidylcholine and [3H] triolein uptake are shown in Figure 1C and 1D.
Plasma levels of RGZ and PGZ following nebulization
Pioglitazone (0.83 ± 0.26 mg/mL (males); 0.99 ± 0.21 (females) and RGZ (0.2 ± 0.075 
(male); 0.4 ± 0.08 mg/mL (female] were detectable in the plasma of males and females, 24h 
after nebulization. Though female RGZ plasma levels were significantly higher than in 
males, there were no statistically significant differences in PGZ plasma levels between the 
males and females. At the 72h time point, the plasma PGZ level for the combined gender 
group was 0.52 ± 0.15 µg/mL. As expected, PGZ and RGZ levels were undetectable in 
plasma samples from control groups.
Effects of nebulized RGZ and PGZ on extrapulmonary PPARγ-expressing organs
To assess the effects of nebulized RGZ and PGZ on extrapulmonary PPARγ-expressing 
organs such as the liver, heart and kidney, 24h after nebulization, PPARγ protein levels in 
these tissues were determined. Only in the livers of the PGZ nebulized animals (both 
females and males) were the PPARγ protein levels significantly increased, while there were 
no significant effects on PPARγ protein levels in the hearts and kidneys of either the PGZ or 
RGZ nebulized animals (data not shown).
Having demonstrated that nebulized RGZ and PGZ administration enhanced neonatal rat 
lung maturation, we next examined whether nebulized PGZ provided any protection against 
hyperoxia-induced neonatal lung injury. For this, we administered nebulized PGZ once daily 
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(q 24h), starting on day 1 of life, for up to 72h, and exposed the pups to either normoxia or 
hyperoxia (95% O2) during the experimental period.
Effects of nebulized PGZ on hyperoxia-induced neonatal lung injury
Compared to the controls, the BAL total cell count (Figure 3A), macrophage count (Figure 
3B), and protein content (Figure 3C) after exposure to hyperoxia increased significantly, 
effects that were counteracted in the PGZ nebulized group. Examining markers of alveolar 
differentiation indicated significant decreases in triolein uptake (Figure 4A), PPARγ (Figure 
4B) and ADRP (Figure 4C) protein levels, and significant increases in fibronectin (Figure 
4D) protein levels in the hyperoxia-exposed group (p<0.05 vs. control); all of these changes 
were blocked in the PGZ nebulized group. Hyperoxia-induced decreases in vascular markers 
such as VEGF (Figure 5A) and PECAM-1 (Figure 5B) were blocked with PGZ nebulization. 
Similarly, hyperoxia-induced alterations in the lung cytokine (IL-6, IL-1β, CCL-2, MIF) 
profile were blocked in the PGZ nebulized group (Figures 6A–6D). Hyperoxia-induced lung 
injury, as reflected by the decreased BcL2/Bax protein ratio, was also blocked by PGZ 
nebulization (Figure 6E). In line with these data, and perhaps even more importantly, 
hyperoxia-induced lung morphometric changes, as determined by radial alveolar count and 
mean linear intercept, were also blocked in the PGZ nebulized group (Figure 7). To compare 
the efficacy of protection against hyperoxia-induced neonatal lung injury, using nebulized 
PGZ (1 mg/kg body weight) versus that afforded by the intraperitoneally administered PGZ 
(3 mg/kg body weight), alterations in select injury repair markers (PPARγ, ADRP, BcL2, 
and fibronectin) were determined. There was equally effective protection in hyperoxia-
induced alterations in these markers using the lower nebulized dose versus the higher 
intraperitoneally administered dose (Figure 8).
Lastly, since hyperoxia-induced neonatal lung injury is known to be mediated via TGF-β 
activation (9, 10), we next determined the effect of nebulized PGZ on hyperoxia-induced 
alterations in key intermediates of TGF-β activation. As expected, p-Smad3, Smad7, and 
ALK-5 (TGF- β II receptor) protein levels were significantly increased in the hyperoxia 
exposure group, with blockade of this response in the PGZ- nebulized group (Figure 9).
Discussion
In this study, we demonstrate that the PPARγ agonists RGZ and PGZ, given via nebulization 
to newborn Sprague Dawley rat pups result in enhanced lung maturation, in both male and 
female neonatal rat pups equally, as evidenced by the increased expression of alveolar 
epithelial (SPB, SPC, surfactant phospholipid synthesis) and mesenchymal (PPARγ, ADRP, 
and leptin protein levels, and triolein uptake) maturation markers. Furthermore, the 
nebulized PPARγ approach also protected against hyperoxia-induced neonatal lung injury, 
since hyperoxia-induced changes in BAL cell and protein contents, lung tissue maturation 
and injury markers (BcL2, Bax, and TGF-β activation markers) were all blocked by 
nebulized PGZ. In general the effects of nebulized RGZ or PGZ (3mg/kg) on alveolar 
mesenchymal and epithelial differentiation markers seem to be similar to the previously 
reported effects following intraperitoneal administration of RGZ at a comparable dose (3); 
however, at a lower dose (1 mg/kg body weight), nebulized PGZ, seems to be equally 
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effective in preventing hyperoxia-induced neonatal lung injury compared to the protection 
afforded with a relatively higher parenterally-administered dose (3 mg/kg body weight). 
Therefore, it seems that administration of nebulized PPARγ agonists represents an effective 
strategy for enhancing postnatal lung maturation, preventing neonatal hyperoxia-induced 
lung injury in both males and females.
Since, pulmonary immaturity is the main contributor to the morbidity and mortality of 
premature infants (20), it is of great relevance to determine novel and safer agents to 
stimulate lung maturation, acting in a non-gender discriminatory manner. Other than 
antenatal steroids, no intervention has proven effective in enhancing lung maturation, let 
alone preventing hyperoxia-induced lung damage (5, 21). A number of recent studies have 
suggested PPARγ agonists as potential lung maturation and protection agents (3, 9–12, 22–
24). The prior work on the use of PPARγ agonists to enhance lung maturation has also 
shown that both antenatal and postnatal intraperitoneal RGZ administration block 
hyperoxia-induced lung molecular and morphometric changes postnatally (9, 10). Therefore, 
it should not be surprising that in line with the previous work, nebulized PGZ stimulated 
alveolar maturation and protection against hyperoxia-induced neonatal lung injury, since 
lipofibroblast differentiation is driven by PPARγ, and since lipofibroblasts are known to be 
cytoprotective against oxidant injury, and produce specific growth and differentiation and 
homeostasis (1, 4, 25). However, in adults the chronic use of PPARγ agonists has been 
shown to be associated with significant side effects, e.g. cardiovascular effects with RGZ, 
and bladder cancer with PGZ (14–17, 26). In line with our prior studies, where we have 
shown that RGZ given parenterally, either antenatally or postnatally, doesn’t affect either 
cardiac troponin or any of the other metabolic parameters examined, such as the blood lipid 
profile and glucose and insulin tolerance tests (3, 11–13), in this study too, plasma cardiac 
troponin levels were undetectable in both control and hyperoxia-exposed animals with or 
without PGZ treatment.
We found that even when given via nebulization, both RGZ and PGZ seem to be 
systemically absorbed, as reflected by detectable plasma levels. However, other than the 
increase in the PPARγ protein levels in the livers of PGZ and RGZ nebulized animals, there 
seem to be no effects on either PPARγ or its downstream targets, such as ADRP and leptin 
protein levels (data not shown), in any other PPARγ-expressing extra-pulmonary organs 
such as the heart and kidney, by either RGZ or PGZ.
In summary, treatment with nebulized PPARγ agonist accelerated neonatal lung maturation 
and prevented hyperoxia-induced lung injury, representing an effective and potentially safe 
therapeutic strategy. Though more work needs to be done to establish the safety profile and 
effective clinical use in neonates, the work presented here provides further proof-of-
principle for the beneficial effects of this class of drugs in the prevention and management 
of neonatal lung injury.
Acknowledgments
Grant Support: National Institute of Health (HL075405, HL55268, HD51857, HD058948, HL107118, and 
HD071731)
Morales et al. Page 8
Pediatr Res. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
References
1. Torday JS, Torres E, Rehan VK. The role of fibroblast transdifferentiation in lung epithelial cell 
proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med. 2003; 22:189–207. 
[PubMed: 12746170] 
2. Simon DM, Arikan MC, Srisuma S, et al. Epithelial cell PPAR [gamma] contributes to normal lung 
maturation. FASEB J. 2006; 20:1507–1509. [PubMed: 16720732] 
3. Wang Y, Sakurai R, Cerny L, et al. Peroxisome proliferator-activated receptor (PPAR)γ agonist 
enhance lung maturation in neonatal rat model. Pediatr Res. 2009; 65:150–152. [PubMed: 
19262292] 
4. Torday JS, Torday DP, Gutnick J, et al. Biologic role of fetal lung fibroblast triglycerides as 
antioxidants. Pediatr Res. 2001; 49:843–849. [PubMed: 11385147] 
5. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on 
Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 
1995; 273:413–418. [PubMed: 7823388] 
6. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal 
corticosteroids. N Engl J Med. 2007; 357:1190–1198. [PubMed: 17881751] 
7. Ballard PL, Ballard RA, Granberg JP, et al. Fetal sex and prenatal betamethasone therapy. J Pediatr. 
1980; 97:451–454. [PubMed: 7411310] 
8. Nielsen, HC.; Torday, JS. Sex differences in fetal lung development: Biology, Etiology, and 
Evolutionary Significance. In: Mendelson, CR., editor. Endocrinology of the Lung-Development 
and Surfactant Synthesis. Totowa, New Jersey: Humana Press; 2000. p. 141-159.
9. Rehan, Virender K.; Sakurai, Reiko, et al. Antenatally Administered PPAR-gamma Agonist 
Rosiglitazone Prevents Hyperoxia-induced Neonatal Rat Lung Injury. Am J Physiol Lung Cell Mol 
Physiol. 2010; 299:L672–L680. [PubMed: 20729387] 
10. Dasgupta C, Sakurai R, Wang Y, et al. Hyperoxia-induced neonatal lung injury involves activation 
of TGF- β and Wnt signaling and is protected by rosiglitazone. Am J physiol Lung Cell Mol 
Physiol. 2009; 296:L1031–L1041. [PubMed: 19304912] 
11. Truong NC, Abbasi A, Sakurai R, Paul W, Torday JS, Rehan VK. Postnatal rosiglitazone 
administration to neonatal rat pups does not alter the young adult metabolic phenotype. 
Neonatology. 2012; 101:217–224. [PubMed: 22076469] 
12. Sierra H, Sakurai R, Lee Wai-Nang, et al. Prenatal rosiglitazone administration to neonatal rat pups 
does not alter the adult metabolic phenotype. PPAR Res. 2012 e-pub 3 July 2012. 
13. Rehan VK, Wang Y, Sugano S, Santos J, Patel S, Sakurai R, Boros LG, Lee WP, Torday JS. In 
utero nicotine exposure alters fetal rat lung alveolat type II cell proliferation, differentiation, and 
metabolism. Am J Physiol Lung Cell Mol Physiol. 2007; 292:L323–L333. 2007. [PubMed: 
17215434] 
14. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 
diabetes: data from the RECORD clinical trial. Eur Heart J. 2010; 31:824–831. [PubMed: 
20118174] 
15. Leal I, Romio SA, Schuemie M, et al. Prescribing pattern of glucose lowering drugs in the United 
Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin 
Pharmacol. 2013; 75:861–868. [PubMed: 22845019] 
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from 
cardiovascular causes. N Engl J Med. 2007; 356:2457–2471. [PubMed: 17517853] 
17. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated 
with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug 
Saf. 2009; 32:787–800. [PubMed: 19670918] 
18. Abbas A, Blandon J, Rude J, et al. PPAR-γ agonist in treatment of diabetes: cardiovascular safety 
considerations. Cardiovasc Hematol Agents Med Chem. 2012; 10:124–134. [PubMed: 22471957] 
19. Rehan VK, Sakurai R, Li Y, et al. Effects of maternal food restriction on offspring lung, 
extracellular matrix deposition and long term pulmonary function in an experimental rat model. 
Pediatr Pulmunology. 2012; 47:162–171.
Morales et al. Page 9
Pediatr Res. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
20. Behrman, RE.; Butler, AS., editors. Institute of Medicine (US) Committee on Understanding 
Premature Birth and Assuring Healthy Outcomes. Washington (DC): National Academies Press 
(US); 2007. Preterm Birth: Causes, Consequences, and Prevention. 
21. Crane J, Armson A, Brunner M, et al. Executive Committee of the Society of Obstetricians and 
Gynaecologists of Canada. Antenatal corticosteroid therapy for fetal maturation. J Obstet 
Gynaecol Can. 2003; 25:45–52. [PubMed: 12548324] 
22. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-
prostagalndin J2 on bleomycin-induced lung injury. Eur Respir J. 2005; 25:225–234. [PubMed: 
15684285] 
23. Liu D, Zeng BX, Zhang SH, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated 
receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. 
Inflamm Res. 2005; 54:464–470. [PubMed: 16307220] 
24. Groomes J, Morgelin M, Soehnlein O. Pioglitazone attenuates endotoxin-induced acute lung injury 
by reducing neutrophil recruitment. Eur Respir J. 2012; 40:416–423. e-pub 20 Jan 2012. [PubMed: 
22267758] 
25. Torday JS, Rehan VK. Stretch-stimulated surfactant synthesis is coordinated by the paracrine 
actions of PTHrP and leptin. Am J Physiol Lung Cell Mol Physiol. 2002; 283:L130–L135. 
[PubMed: 12060569] 
26. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of 
controlled studies. Diabet Med. 2013; 30:1026–1032. [PubMed: 23350856] 
Morales et al. Page 10
Pediatr Res. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Effects of nebulized RGZ or PGZ on alveolar epithelial and mesenchymal 
differentiation markers in the female and male rat pup lung
Twenty-four hour following either RGZ or PGZ nebulization resulted in increased 
expression of SP-B and SP-C in both females and males (A). Similarly, either PGZ or RGZ 
stimulated the alveolar mesenchymal differentiation markers PPARγ, ADRP and leptin in 
both females and males (B); n=4; *, p<0.05, control vs. treated animals. Either nebulized 
RGZ or PGZ also increased [3H]choline incorporation (C) and triolein uptake (D); n=6; *, 
p<0.05, control vs. treated animals. White bars, controls; black bars, PGZ group; and gray 
bars, RGZ group.
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Figure 2. Comparative effects of nebulized RGZ or PGZ on the expression of alveolar epithelial 
and mesenchymal differentiation markers in the female and male neonatal rat pup
There were no significant differences in the lung protein levels of epithelial, SPB and SPC 
(A), and mesenchymal, PPARγ, ADRP and leptin, (B), differentiation markers in the female 
(white bars) and male (black bars) newborn rat pup, 24h following nebulized RGZ or PGZ 
(n=4; p>0.05, control vs. treated animals).
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Figure 3. Effect of nebulized PGZ on total bronchoalveolar lavage cell count (A), macrophage 
count (B), and total protein (C) content after exposure of neonatal rat lung to hyperoxia (95% 
O2) for 72h
When exposed to hyperoxia, the bronchoalveolar lavage total cell counts increased 6-fold, 
macrophage count and total protein content increased 3-fold each. In contrast, with 
nebulized PGZ, all of these BAL changes were blocked. White bars, 21% O2; black bars, 
95% O2; and gray bars, 95% O2 + PGZ. n=4; *, p<0.05 vs. control; **, p<0.05 vs. 95% O2.
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Figure 4. Effect of nebulized PGZ on neonatal rat lung triolein uptake and lung injury repair 
protein levels
When neonatal rat pups were exposed to hyperoxia for 72h, triolein uptake was diminished 
compared to controls. In contrast, triolein uptake was clearly stimulated by treatment with 
nebulized PGZ after 72h exposure to hyperoxia (A). Similarly, PPARγ (B) and ADRP (C) 
protein levels decreased and fibronectin (D) protein levels increased in the hyperoxia-
exposed group (p<0.05 vs. control); all of these changes were blocked in the PGZ nebulized 
group. White bars, 21% O2; black bars, 95% O2; and gray bars, 95% O2 + PGZ (n=4 for all; 
*, p<0.05 vs. control; **, p<0.05 vs. 95% O2).
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Figure 5. Effect of nebulized PGZ on hyperoxia-induced alterations in neonatal rat lung vascular 
markers VEGF and PECAM-1
As determined by immunostaining, 72h hyperoxia-induced decreases in vascular markers 
VEGF and PECAM-1 were blocked with PGZ nebulization.
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Figure 6. Effect of nebulized PGZ on hyperoxia-induced changes in neonatal rat lung 
inflammation-related cytokines and apoptosis (determined by BcL2/Bax protein ratio)
Seventy-two hour hyperoxia exposure-induced alterations in lung cytokines, IL-6, (A), 
IL-1β (B), CCL-2 (C), and MIF (D), were blocked in the PGZ nebulized group, as was the 
decrease in BcL2/Bax protein ratio (E). White bars, 21% O2; black bars, 95% O2; and gray 
bars, 95% O2 + PGZ (n=4 for all; *, p<0.05 vs. control; **, p<0.05 vs. 95% O2).
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Figure 7. Effect of nebulized PGZ on hyperoxia-induced changes in lung morphometry
Seventy-two hour hyperoxia exposure-induced lung morphometric changes, as determined 
by mean linear intercept and radial alveolar count, were blocked in the PGZ nebulized 
group. White bars, 21% O2; black bars, 95% O2; and gray bars, 95% O2 + PGZ (n=4 for all; 
*, p<0.05 vs. control; **, p<0.05 vs. 95% O2; magnification = 10×).
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Figure 8. Comparison of the efficacy for protection against hyperoxia-induced lung injury using 
nebulized PGZ (1 mg/kg body weight) with that afforded by intraperitoneal PGZ (3 mg/kg body 
weight)
Nebulized PGZ at a lower dose (1 mg/kg/ body weight) was equally effective in blocking 
hyperoxia induced decreases in PPARγ, ADRP, and BcL2, and increase in fibronectin 
protein levels compared to that achieved by the higher intraperitoneally administered dose (3 
mg/kg body weight). White bars, 21% O2; black bars, 95% O2; gray bars, 95% O2 + 
nebulized PGZ; hatched bars, 95% O2 + intraperitoneal PGZ. N=3 for all; *, p<0.05 vs. 
control; **, p<0.05 vs. 95% O2.
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Figure 9. Effect of nebulized PGZ on hyperoxia-induced changes in key intermediates of TGF-β 
activation
When newborn rat lung was exposed to 72h hyperoxia, P-Smad 3 (A), Smad 7 (B) and ALK 
5 (C) expression increased. In contrast, treatment with nebulized PGZ daily during the 72 h 
hyperoxia exposure prevented the stimulation of all of these TGF-β activation markers. 
White bars, 21% O2; black bars, 95% O2; and gray bars, 95% O2 + PGZ. N=4; *, p<0.05 vs. 
control; **, p<0.05 vs. 95% O2.
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